{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:03:42Z","timestamp":1790348622282,"version":"4.1.0"},"reference-count":130,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Cardiovasc. Transl. Res."],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s12265-026-10847-8","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:36:48Z","timestamp":1790347008000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Next-Generation Bone Marrow Cell Therapies for Cardiac Repair: Integrating Gene Therapy and Bioengineering to Enhance Therapeutic Potency"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1644-7061","authenticated-orcid":false,"given":"Busra","family":"Cesur Ergun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9644-7610","authenticated-orcid":false,"given":"Busra","family":"Cetin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7386-6871","authenticated-orcid":false,"given":"Ozgur","family":"Dandin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8379-5678","authenticated-orcid":false,"given":"Salih","family":"Sanlioglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"issue":"10","key":"10847_CR1","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41569-018-0036-6","volume":"15","author":"H Hashimoto","year":"2018","unstructured":"Hashimoto H, Olson EN, Bassel-Duby R. Therapeutic approaches for cardiac regeneration and repair. Nat Rev Cardiol. 2018;15(10):585\u2013600. https:\/\/doi.org\/10.1038\/s41569-018-0036-6.","journal-title":"Nat Rev Cardiol"},{"issue":"25","key":"10847_CR2","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1016\/j.jacc.2023.11.007","volume":"82","author":"GA Mensah","year":"2023","unstructured":"Mensah GA, Fuster V, Murray CJL, Roth GA. Global Burden of Cardiovascular Diseases and Risks, 1990\u20132022. J Am Coll Cardiol. 2023;82(25):2350\u2013473. https:\/\/doi.org\/10.1016\/j.jacc.2023.11.007.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10847_CR3","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1186\/s12872-025-05022-x","volume":"25","author":"L Yang","year":"2025","unstructured":"Yang L, Zheng B, Gong Y. Global, regional and national burden of ischemic heart disease and its attributable risk factors from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021. BMC Cardiovasc Disord. 2025;25(1):625. https:\/\/doi.org\/10.1186\/s12872-025-05022-x.","journal-title":"BMC Cardiovasc Disord"},{"issue":"6","key":"10847_CR4","doi-asserted-by":"publisher","first-page":"434","DOI":"10.5966\/sctm.2013-0001","volume":"2","author":"S Koudstaal","year":"2013","unstructured":"Koudstaal S, Jansen of Lorkeers SJ, Gaetani R, Gho JMIH, van Slochteren FJ, Sluijter JPG, et al. Concise Review: Heart Regeneration and the Role of Cardiac Stem Cells. STEM CELLS Translational Med. 2013;2(6):434\u201343. https:\/\/doi.org\/10.5966\/sctm.2013-0001.","journal-title":"STEM CELLS Translational Med"},{"issue":"7","key":"10847_CR5","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1161\/circulationaha.117.029343","volume":"136","author":"T Eschenhagen","year":"2017","unstructured":"Eschenhagen T, Bolli R, Braun T, Field LJ, Fleischmann BK, Fris\u00e9n J, et al. Cardiomyocyte Regeneration: A Consensus Statement. Circulation. 2017;136(7):680\u20136. https:\/\/doi.org\/10.1161\/circulationaha.117.029343.","journal-title":"Circulation"},{"issue":"5923","key":"10847_CR6","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1126\/science.1164680","volume":"324","author":"O Bergmann","year":"2009","unstructured":"Bergmann O, Bhardwaj RD, Bernard S, Zdunek S, Barnab\u00e9-Heider F, Walsh S, et al. Evidence for Cardiomyocyte Renewal in Humans. Science. 2009;324(5923):98\u2013102. https:\/\/doi.org\/10.1126\/science.1164680.","journal-title":"Science"},{"issue":"1","key":"10847_CR7","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1186\/s13287-025-04357-8","volume":"16","author":"M Mahnoor","year":"2025","unstructured":"Mahnoor M, Hassan SI, Bakhtiar M, Sharjeel S, Daneyal R, Ibrahim M, et al. Cardiomyocyte regeneration therapy and its effect on LVEF and scar size- a systematic review and meta-analysis. Stem Cell Res Ther. 2025;16(1):485. https:\/\/doi.org\/10.1186\/s13287-025-04357-8.","journal-title":"Stem Cell Res Ther"},{"issue":"1","key":"10847_CR8","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1186\/s13287-021-02667-1","volume":"12","author":"A Attar","year":"2021","unstructured":"Attar A, Bahmanzadegan Jahromi F, Kavousi S, Monabati A, Kazemi A. Mesenchymal stem cell transplantation after acute myocardial infarction: a meta-analysis of clinical trials. Stem Cell Res Ther. 2021;12(1):600. https:\/\/doi.org\/10.1186\/s13287-021-02667-1.","journal-title":"Stem Cell Res Ther"},{"key":"10847_CR9","doi-asserted-by":"publisher","unstructured":"Fisher SA, Brunskill SJ, Doree C, Mathur A, Taggart DP, Martin-Rendon E. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst Rev. 2014;4Cd007888. https:\/\/doi.org\/10.1002\/14651858.CD007888.pub2.","DOI":"10.1002\/14651858.CD007888.pub2"},{"issue":"6","key":"10847_CR10","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1161\/CIRCRESAHA.114.304792","volume":"117","author":"MR Afzal","year":"2015","unstructured":"Afzal MR, Samanta A, Shah ZI, Jeevanantham V, Abdel-Latif A, Zuba-Surma EK, et al. Adult Bone Marrow Cell Therapy for Ischemic Heart Disease. Circul Res. 2015;117(6):558\u201375. https:\/\/doi.org\/10.1161\/CIRCRESAHA.114.304792.","journal-title":"Circul Res"},{"issue":"19","key":"10847_CR11","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1001\/jama.2011.1670","volume":"306","author":"JH Traverse","year":"2011","unstructured":"Traverse JH, Henry TD, Ellis SG, Pepine CJ, Willerson JT, Zhao DX, et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA. 2011;306(19):2110\u20139. https:\/\/doi.org\/10.1001\/jama.2011.1670.","journal-title":"JAMA"},{"issue":"5","key":"10847_CR12","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1161\/CIRCULATIONAHA.111.086074","volume":"126","author":"V Jeevanantham","year":"2012","unstructured":"Jeevanantham V, Butler M, Saad A, Abdel-Latif A, Zuba-Surma EK, Dawn B. Adult Bone Marrow Cell Therapy Improves Survival and Induces Long-Term Improvement in Cardiac Parameters. Circulation. 2012;126(5):551\u201368. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.111.086074.","journal-title":"Circulation"},{"issue":"15","key":"10847_CR13","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1136\/heartjnl-2014-305646","volume":"100","author":"MJ Goumans","year":"2014","unstructured":"Goumans MJ, Maring JA, Smits AM. A straightforward guide to the basic science behind cardiovascular cell-based therapies. Heart. 2014;100(15):1153\u20137. https:\/\/doi.org\/10.1136\/heartjnl-2014-305646.","journal-title":"Heart"},{"issue":"1","key":"10847_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1161\/circresaha.115.305373","volume":"118","author":"CP Hodgkinson","year":"2016","unstructured":"Hodgkinson CP, Bareja A, Gomez JA, Dzau VJ. Emerging Concepts in Paracrine Mechanisms in Regenerative Cardiovascular Medicine and Biology. Circ Res. 2016;118(1):95\u2013107. https:\/\/doi.org\/10.1161\/circresaha.115.305373.","journal-title":"Circ Res"},{"issue":"3","key":"10847_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1139\/cjpp-2023-0202","volume":"102","author":"JK Gill","year":"2024","unstructured":"Gill JK, Rehsia SK, Verma E, Sareen N, Dhingra S. Stem cell therapy for cardiac regeneration: past, present, and future. Can J Physiol Pharmacol. 2024;102(3):161\u201379. https:\/\/doi.org\/10.1139\/cjpp-2023-0202.","journal-title":"Can J Physiol Pharmacol"},{"key":"10847_CR16","doi-asserted-by":"publisher","unstructured":"Bollini S, Smits AM, Balbi C, Lazzarini E, Ameri P. Triggering endogenous cardiac repair and regeneration via extracellular vesicle-mediated communication. Front Physiol. 2018;9:1497. https:\/\/doi.org\/10.3389\/fphys.2018.01497.","DOI":"10.3389\/fphys.2018.01497"},{"issue":"11","key":"10847_CR17","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1161\/CIRCRESAHA.108.176826","volume":"103","author":"M Gnecchi","year":"2008","unstructured":"Gnecchi M, Zhang Z, Ni A, Dzau VJ. Paracrine Mechanisms in Adult Stem Cell Signaling and Therapy. Circul Res. 2008;103(11):1204\u201319. https:\/\/doi.org\/10.1161\/CIRCRESAHA.108.176826.","journal-title":"Circul Res"},{"issue":"2","key":"10847_CR18","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.yjmcc.2010.08.005","volume":"50","author":"M Mirotsou","year":"2011","unstructured":"Mirotsou M, Jayawardena TM, Schmeckpeper J, Gnecchi M, Dzau VJ. Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. J Mol Cell Cardiol. 2011;50(2):280\u20139. https:\/\/doi.org\/10.1016\/j.yjmcc.2010.08.005.","journal-title":"J Mol Cell Cardiol"},{"issue":"6","key":"10847_CR19","doi-asserted-by":"publisher","first-page":"e22","DOI":"10.1161\/CIRCRESAHA.117.310803","volume":"121","author":"A Tachibana","year":"2017","unstructured":"Tachibana A, Santoso MR, Mahmoudi M, Shukla P, Wang L, Bennett M, et al. Paracrine Effects of the Pluripotent Stem Cell-Derived Cardiac Myocytes Salvage the Injured Myocardium. Circul Res. 2017;121(6):e22\u201336. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.310803.","journal-title":"Circul Res"},{"issue":"8","key":"10847_CR20","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1007\/s12015-022-10429-6","volume":"18","author":"NS Mabotuwana","year":"2022","unstructured":"Mabotuwana NS, Rech L, Lim J, Hardy SA, Murtha LA, Rainer PP, et al. Paracrine Factors Released by Stem Cells of Mesenchymal Origin and their Effects in Cardiovascular Disease: A Systematic Review of Pre-clinical Studies. Stem Cell Rev Rep. 2022;18(8):2606\u201328. https:\/\/doi.org\/10.1007\/s12015-022-10429-6.","journal-title":"Stem Cell Rev Rep"},{"issue":"12","key":"10847_CR21","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1253\/circj.CJ-19-0567","volume":"83","author":"K Nakamura","year":"2019","unstructured":"Nakamura K, Murry CE. Function Follows Form\u3000- A Review of Cardiac Cell Therapy. Circ J. 2019;83(12):2399\u2013412. https:\/\/doi.org\/10.1253\/circj.CJ-19-0567.","journal-title":"Circ J"},{"issue":"11","key":"10847_CR22","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1161\/CIRCRESAHA.108.175943","volume":"102","author":"S Dimmeler","year":"2008","unstructured":"Dimmeler S, Leri A. Aging and Disease as Modifiers of Efficacy of Cell Therapy. Circul Res. 2008;102(11):1319\u201330. https:\/\/doi.org\/10.1161\/CIRCRESAHA.108.175943.","journal-title":"Circul Res"},{"issue":"1","key":"10847_CR23","doi-asserted-by":"publisher","first-page":"biores","DOI":"10.1089\/biores.2014.0042","volume":"4","author":"AY Efimenko","year":"2015","unstructured":"Efimenko AY, Kochegura TN, Akopyan ZA, Parfyonova YV. Autologous Stem Cell Therapy: How Aging and Chronic Diseases Affect Stem and Progenitor Cells. BioResearch Open Access. 2015;4(1):biores. 2014.0042.","journal-title":"BioResearch Open Access"},{"issue":"24","key":"10847_CR24","doi-asserted-by":"publisher","first-page":"12641","DOI":"10.18632\/aging.102592","volume":"11","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Zhu W, He H, Fan B, Deng R, Hong Y, et al. Macrophage migration inhibitory factor rejuvenates aged human mesenchymal stem cells and improves myocardial repair. Aging. 2019;11(24):12641\u201360. https:\/\/doi.org\/10.18632\/aging.102592.","journal-title":"Aging"},{"key":"10847_CR25","doi-asserted-by":"publisher","unstructured":"Gao S, Li D, Wang B, Zhang H, Chen L. Two promising approaches in the treatment of myocardial infarction: stem cells and gene therapy. Front Cardiovasc Med. 2025;12\u20132025. https:\/\/doi.org\/10.3389\/fcvm.2025.1540066.","DOI":"10.3389\/fcvm.2025.1540066"},{"issue":"17","key":"10847_CR26","doi-asserted-by":"publisher","first-page":"e70056","DOI":"10.1111\/jcmm.70056","volume":"28","author":"B Cetin","year":"2024","unstructured":"Cetin B, Erendor F, Eksi YE, Sanlioglu AD, Sanlioglu S. Gene and cell therapy of human genetic diseases: Recent advances and future directions. J Cell Mol Med. 2024;28(17):e70056. https:\/\/doi.org\/10.1111\/jcmm.70056.","journal-title":"J Cell Mol Med"},{"key":"10847_CR27","unstructured":"FDA. FDA Increases Flexibility on Requirements for Cell and Gene Therapies to Advance Innovation. (2026). https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-increases-flexibility-requirements-cell-and-gene-therapies-advance-innovation?utm_source=chatgpt.com. Accessed 20 May 2026."},{"issue":"2","key":"10847_CR28","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1161\/circresaha.117.311302","volume":"123","author":"M Gy\u00f6ngy\u00f6si","year":"2018","unstructured":"Gy\u00f6ngy\u00f6si M, Haller PM, Blake DJ, Martin Rendon E. Meta-Analysis of Cell Therapy Studies in Heart Failure and Acute Myocardial Infarction. Circ Res. 2018;123(2):301\u20138. https:\/\/doi.org\/10.1161\/circresaha.117.311302.","journal-title":"Circ Res"},{"issue":"17","key":"10847_CR29","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1161\/01.CIR.0000163546.27639.AA","volume":"111","author":"M Hofmann","year":"2005","unstructured":"Hofmann M, Wollert KC, Meyer GP, Menke A, Arseniev L, Hertenstein B, et al. Monitoring of Bone Marrow Cell Homing Into the Infarcted Human Myocardium. Circulation. 2005;111(17):2198\u2013202. https:\/\/doi.org\/10.1161\/01.CIR.0000163546.27639.AA.","journal-title":"Circulation"},{"issue":"4","key":"10847_CR30","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.yjmcc.2008.03.009","volume":"45","author":"TE Robey","year":"2008","unstructured":"Robey TE, Saiget MK, Reinecke H, Murry CE. Systems approaches to preventing transplanted cell death in cardiac repair. J Mol Cell Cardiol. 2008;45(4):567\u201381. https:\/\/doi.org\/10.1016\/j.yjmcc.2008.03.009.","journal-title":"J Mol Cell Cardiol"},{"issue":"5","key":"10847_CR31","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrcardio.2014.28","volume":"11","author":"NG Frangogiannis","year":"2014","unstructured":"Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Reviews Cardiol. 2014;11(5):255\u201365. https:\/\/doi.org\/10.1038\/nrcardio.2014.28.","journal-title":"Nat Reviews Cardiol"},{"issue":"3","key":"10847_CR32","doi-asserted-by":"publisher","first-page":"H448","DOI":"10.1152\/ajpheart.00287.2018","volume":"315","author":"H Shakeri","year":"2018","unstructured":"Shakeri H, Lemmens K, Gevaert AB, De Meyer GRY, Segers VFM. Cellular senescence links aging and diabetes in cardiovascular disease. Am J Physiol Heart Circ Physiol. 2018;315(3):H448\u201362. https:\/\/doi.org\/10.1152\/ajpheart.00287.2018.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"3","key":"10847_CR33","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1161\/circresaha.109.208991","volume":"106","author":"JV Terrovitis","year":"2010","unstructured":"Terrovitis JV, Smith RR, Marb\u00e1n E. Assessment and optimization of cell engraftment after transplantation into the heart. Circ Res. 2010;106(3):479\u201394. https:\/\/doi.org\/10.1161\/circresaha.109.208991.","journal-title":"Circ Res"},{"issue":"2","key":"10847_CR34","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jss.2007.03.021","volume":"142","author":"W Hudson","year":"2007","unstructured":"Hudson W, Collins MC, deFreitas D, Sun YS, Muller-Borer B, Kypson AP. Beating and arrested intramyocardial injections are associated with significant mechanical loss: implications for cardiac cell transplantation. J Surg Res. 2007;142(2):263\u20137. https:\/\/doi.org\/10.1016\/j.jss.2007.03.021.","journal-title":"J Surg Res"},{"issue":"6","key":"10847_CR35","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3727\/096368911X627381","volume":"21","author":"K Cheng","year":"2012","unstructured":"Cheng K, Malliaras K, Li T-S, Sun B, Houde C, Galang G, et al. Magnetic Enhancement of Cell Retention, Engraftment, and Functional Benefit after Intracoronary Delivery of Cardiac-Derived Stem Cells in a Rat Model of Ischemia\/Reperfusion. Cell Transplant. 2012;21(6):1121\u201335. https:\/\/doi.org\/10.3727\/096368911X627381.","journal-title":"Cell Transplant"},{"issue":"Suppl 2","key":"10847_CR36","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1038\/sj.cdd.4401723","volume":"12","author":"AP Gilmore","year":"2005","unstructured":"Gilmore AP, Anoikis. Cell Death Differ. 2005;12(Suppl 2):1473\u20137. https:\/\/doi.org\/10.1038\/sj.cdd.4401723.","journal-title":"Cell Death Differ"},{"issue":"5b","key":"10847_CR37","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1111\/j.1582-4934.2008.00457.x","volume":"12","author":"C Nesselmann","year":"2008","unstructured":"Nesselmann C, Ma N, Bieback K, Wagner W, Ho A, Konttinen YT, et al. Mesenchymal stem cells and cardiac repair. J Cell Mol Med. 2008;12(5b):1795\u2013810. https:\/\/doi.org\/10.1111\/j.1582-4934.2008.00457.x.","journal-title":"J Cell Mol Med"},{"issue":"8","key":"10847_CR38","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nrm3620","volume":"14","author":"FM Watt","year":"2013","unstructured":"Watt FM, Huck WT. Role of the extracellular matrix in regulating stem cell fate. Nat Rev Mol Cell Biol. 2013;14(8):467\u201373. https:\/\/doi.org\/10.1038\/nrm3620.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"10847_CR39","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1161\/CIRCRESAHA.119.311148","volume":"125","author":"NG Frangogiannis","year":"2019","unstructured":"Frangogiannis NG. The Extracellular Matrix in Ischemic and Nonischemic Heart Failure. Circul Res. 2019;125(1):117\u201346. https:\/\/doi.org\/10.1161\/CIRCRESAHA.119.311148.","journal-title":"Circul Res"},{"key":"10847_CR40","doi-asserted-by":"publisher","first-page":"135","DOI":"10.3389\/fphar.2017.00135","volume":"8","author":"L Li","year":"2017","unstructured":"Li L, Guan Q, Dai S, Wei W, Zhang Y. Integrin \u03b21 Increases Stem Cell Survival and Cardiac Function after Myocardial Infarction. Front Pharmacol. 2017;8:135. https:\/\/doi.org\/10.3389\/fphar.2017.00135.","journal-title":"Front Pharmacol"},{"issue":"1","key":"10847_CR41","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1038\/ncpcardio0441","volume":"3","author":"V Sch\u00e4chinger","year":"2006","unstructured":"Sch\u00e4chinger V, Tonn T, Dimmeler S, Zeiher AM. Bone-marrow-derived progenitor cell therapy in need of proof of concept: design of the REPAIR-AMI trial. Nat Clin Pract Cardiovasc Med. 2006;3(1):S23\u20138. https:\/\/doi.org\/10.1038\/ncpcardio0441.","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"2","key":"10847_CR42","doi-asserted-by":"publisher","first-page":"137","DOI":"10.2217\/14796678.3.2.137","volume":"3","author":"JS Mills","year":"2007","unstructured":"Mills JS, Rao SV. REPAIR-AMI: stem cells for acute myocardial infarction. Future Cardiol. 2007;3(2):137\u201340. https:\/\/doi.org\/10.2217\/14796678.3.2.137.","journal-title":"Future Cardiol"},{"issue":"6","key":"10847_CR43","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jacc.2007.10.032","volume":"51","author":"K Lunde","year":"2008","unstructured":"Lunde K, Solheim S, Forfang K, Arnesen H, Brinch L, Bjornerheim R, et al. Anterior myocardial infarction with acute percutaneous coronary intervention and intracoronary injection of autologous mononuclear bone marrow cells: safety, clinical outcome, and serial changes in left ventricular function during 12-months\u2019 follow-up. J Am Coll Cardiol. 2008;51(6):674\u20136. https:\/\/doi.org\/10.1016\/j.jacc.2007.10.032.","journal-title":"J Am Coll Cardiol"},{"issue":"9429","key":"10847_CR44","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/s0140-6736(04)16626-9","volume":"364","author":"KC Wollert","year":"2004","unstructured":"Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004;364(9429):141\u20138. https:\/\/doi.org\/10.1016\/s0140-6736(04)16626-9.","journal-title":"Lancet"},{"issue":"24","key":"10847_CR45","doi-asserted-by":"publisher","first-page":"2978","DOI":"10.1093\/eurheartj\/ehp374","volume":"30","author":"GP Meyer","year":"2009","unstructured":"Meyer GP, Wollert KC, Lotz J, Pirr J, Rager U, Lippolt P, et al. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur Heart J. 2009;30(24):2978\u201384. https:\/\/doi.org\/10.1093\/eurheartj\/ehp374.","journal-title":"Eur Heart J"},{"issue":"8","key":"10847_CR46","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1161\/circresaha.116.304346","volume":"116","author":"M Gy\u00f6ngy\u00f6si","year":"2015","unstructured":"Gy\u00f6ngy\u00f6si M, Wojakowski W, Lemarchand P, Lunde K, Tendera M, Bartunek J, et al. Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res. 2015;116(8):1346\u201360. https:\/\/doi.org\/10.1161\/circresaha.116.304346.","journal-title":"Circ Res"},{"issue":"6","key":"10847_CR47","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1093\/eurheartj\/ehl509","volume":"28","author":"FH Seeger","year":"2007","unstructured":"Seeger FH, Tonn T, Krzossok N, Zeiher AM, Dimmeler S. Cell isolation procedures matter: a comparison of different isolation protocols of bone marrow mononuclear cells used for cell therapy in patients with acute myocardial infarction. Eur Heart J. 2007;28(6):766\u201372. https:\/\/doi.org\/10.1093\/eurheartj\/ehl509.","journal-title":"Eur Heart J"},{"issue":"3","key":"10847_CR48","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1139\/cjpp-2023-0202","volume":"102","author":"JK Gill","year":"2023","unstructured":"Gill JK, Rehsia SK, Verma E, Sareen N, Dhingra S. Stem cell therapy for cardiac regeneration: past, present, and future. Can J Physiol Pharmacol. 2023;102(3):161\u201379. https:\/\/doi.org\/10.1139\/cjpp-2023-0202.","journal-title":"Can J Physiol Pharmacol"},{"issue":"3","key":"10847_CR49","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/sj.mt.6300374","volume":"16","author":"Z Cheng","year":"2008","unstructured":"Cheng Z, Ou L, Zhou X, Li F, Jia X, Zhang Y, et al. Targeted migration of mesenchymal stem cells modified with CXCR4 gene to infarcted myocardium improves cardiac performance. Mol Ther. 2008;16(3):571\u20139. https:\/\/doi.org\/10.1038\/sj.mt.6300374.","journal-title":"Mol Ther"},{"issue":"2","key":"10847_CR50","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.mvr.2010.03.014","volume":"80","author":"T Zhao","year":"2010","unstructured":"Zhao T, Zhao W, Chen Y, Ahokas RA, Sun Y. Vascular endothelial growth factor (VEGF)-A: role on cardiac angiogenesis following myocardial infarction. Microvasc Res. 2010;80(2):188\u201394. https:\/\/doi.org\/10.1016\/j.mvr.2010.03.014.","journal-title":"Microvasc Res"},{"issue":"4","key":"10847_CR51","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.molmed.2004.02.001","volume":"10","author":"DG Duda","year":"2004","unstructured":"Duda DG, Fukumura D, Jain RK. Role of eNOS in neovascularization: NO for endothelial progenitor cells. Trends Mol Med. 2004;10(4):143\u20135. https:\/\/doi.org\/10.1016\/j.molmed.2004.02.001.","journal-title":"Trends Mol Med"},{"issue":"4","key":"10847_CR52","doi-asserted-by":"publisher","first-page":"247","DOI":"10.3390\/biomedicines2040247","volume":"2","author":"S Gallo","year":"2014","unstructured":"Gallo S, Sala V, Gatti S, Crepaldi T. HGF\/Met Axis in Heart Function and Cardioprotection. Biomedicines. 2014;2(4):247\u201362. https:\/\/doi.org\/10.3390\/biomedicines2040247.","journal-title":"Biomedicines"},{"issue":"15","key":"10847_CR53","doi-asserted-by":"publisher","first-page":"7219","DOI":"10.7150\/thno.112077","volume":"15","author":"A Magadum","year":"2025","unstructured":"Magadum A, Mallaredy V, Roy R, Joladarashi D, Thej C, Cheng Z, et al. Phosphoserine aminotransferase 1 promotes serine synthesis pathway and cardiac repair after myocardial infarction. Theranostics. 2025;15(15):7219\u201341. https:\/\/doi.org\/10.7150\/thno.112077.","journal-title":"Theranostics"},{"issue":"4","key":"10847_CR54","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.bbrc.2010.09.076","volume":"401","author":"H Liu","year":"2010","unstructured":"Liu H, Xue W, Ge G, Luo X, Li Y, Xiang H, et al. Hypoxic preconditioning advances CXCR4 and CXCR7 expression by activating HIF-1\u03b1 in MSCs. Biochem Biophys Res Commun. 2010;401(4):509\u201315. https:\/\/doi.org\/10.1016\/j.bbrc.2010.09.076.","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10847_CR55","doi-asserted-by":"publisher","first-page":"73","DOI":"10.21037\/atm-23-1936","volume":"12","author":"KS Seow","year":"2023","unstructured":"Seow KS, Ling APK. Mesenchymal stem cells as future treatment for cardiovascular regeneration and its challenges. Annals Translational Med. 2023;12(4):73.","journal-title":"Annals Translational Med"},{"issue":"4","key":"10847_CR56","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1152\/physiolgenomics.00141.2011","volume":"44","author":"AJ Kriegel","year":"2012","unstructured":"Kriegel AJ, Liu Y, Fang Y, Ding X, Liang M. The miR-29 family: genomics, cell biology, and relevance to renal and cardiovascular injury. Physiol Genomics. 2012;44(4):237\u201344. https:\/\/doi.org\/10.1152\/physiolgenomics.00141.2011.","journal-title":"Physiol Genomics"},{"issue":"3","key":"10847_CR57","doi-asserted-by":"publisher","first-page":"H497","DOI":"10.1152\/ajpheart.00410.2023","volume":"326","author":"AC Improta-Caria","year":"2024","unstructured":"Improta-Caria AC, Rodrigues LF, Joaquim VHA, De Sousa RAL, Fernandes T, Oliveira EM. MicroRNAs regulating signaling pathways in cardiac fibrosis: potential role of the exercise training. Am J Physiol Heart Circ Physiol. 2024;326(3):H497\u2013510. https:\/\/doi.org\/10.1152\/ajpheart.00410.2023.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"10847_CR58","doi-asserted-by":"publisher","first-page":"418","DOI":"10.3892\/ijmm.2017.3019","volume":"40","author":"X Ni","year":"2017","unstructured":"Ni X, Ou C, Guo J, Liu B, Zhang J, Wu Z, et al. Lentiviral vector-mediated co-overexpression of VEGF and Bcl-2 improves mesenchymal stem cell survival and enhances paracrine effects in vitro. Int J Mol Med. 2017;40(2):418\u201326. https:\/\/doi.org\/10.3892\/ijmm.2017.3019.","journal-title":"Int J Mol Med"},{"key":"10847_CR59","doi-asserted-by":"publisher","unstructured":"Zhang H, Zhan Q, Huang B, Wang Y, Wang X. AAV-mediated gene therapy: Advancing cardiovascular disease treatment. Front Cardiovasc Med. 2022;9\u20132022. https:\/\/doi.org\/10.3389\/fcvm.2022.952755.","DOI":"10.3389\/fcvm.2022.952755"},{"issue":"5","key":"10847_CR60","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1042\/bst20243001","volume":"53","author":"CAP Batho","year":"2025","unstructured":"Batho CAP, Hudson JE, Wilson CH. Using modified mRNA for cardiomyocyte proliferation and cardiac genetic disease modelling and treatment. Biochem Soc Trans. 2025;53(5):1151\u201368. https:\/\/doi.org\/10.1042\/bst20243001.","journal-title":"Biochem Soc Trans"},{"key":"10847_CR61","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jconrel.2024.06.023","volume":"372","author":"S Soroudi","year":"2024","unstructured":"Soroudi S, Jaafari MR, Arabi L. Lipid nanoparticle (LNP) mediated mRNA delivery in cardiovascular diseases: Advances in genome editing and CAR T cell therapy. J Control Release. 2024;372:113\u201340. https:\/\/doi.org\/10.1016\/j.jconrel.2024.06.023.","journal-title":"J Control Release"},{"key":"10847_CR62","doi-asserted-by":"publisher","unstructured":"Bonowicz K, Jerka D, Piekarska K, Olagbaju J, Stapleton L, Shobowale M, et al. CRISPR-Cas9 in cardiovascular medicine: Unlocking new potential for treatment. Cells. 2025;14(2). https:\/\/doi.org\/10.3390\/cells14020131.","DOI":"10.3390\/cells14020131"},{"issue":"12","key":"10847_CR63","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1089\/hum.2008.123","volume":"19","author":"LT Bish","year":"2008","unstructured":"Bish LT, Morine K, Sleeper MM, Sanmiguel J, Wu D, Gao G, et al. Adeno-Associated Virus (AAV) Serotype 9 Provides Global Cardiac Gene Transfer Superior to AAV1, AAV6, AAV7, and AAV8 in the Mouse and Rat. Hum Gene Ther. 2008;19(12):1359\u201368. https:\/\/doi.org\/10.1089\/hum.2008.123.","journal-title":"Hum Gene Ther"},{"issue":"3","key":"10847_CR64","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/s1525-0016(02)00061-8","volume":"7","author":"J Yang","year":"2003","unstructured":"Yang J, Marden JJ, Fan C, Sanlioglu S, Weiss RM, Ritchie TC, et al. Genetic redox preconditioning differentially modulates AP-1 and NF kappa B responses following cardiac ischemia\/reperfusion injury and protects against necrosis and apoptosis. Mol Ther. 2003;7(3):341\u201353. https:\/\/doi.org\/10.1016\/s1525-0016(02)00061-8.","journal-title":"Mol Ther"},{"issue":"6148","key":"10847_CR65","doi-asserted-by":"publisher","first-page":"1233158","DOI":"10.1126\/science.1233158","volume":"341","author":"A Biffi","year":"2013","unstructured":"Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, et al. Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy. Science. 2013;341(6148):1233158. https:\/\/doi.org\/10.1126\/science.1233158.","journal-title":"Science"},{"issue":"9","key":"10847_CR66","doi-asserted-by":"publisher","first-page":"4259","DOI":"10.1016\/j.ymthe.2025.06.023","volume":"33","author":"X Zhang","year":"2025","unstructured":"Zhang X, Wang C, Chang Y, Jia H, Zhang Y, Wang Y, et al. AAV9-mediated gene supplementation therapy prevents and rescues arrhythmogenic cardiomyopathy in Pnpla2-mutated mice. Mol Ther. 2025;33(9):4259\u201375. https:\/\/doi.org\/10.1016\/j.ymthe.2025.06.023.","journal-title":"Mol Ther"},{"issue":"1","key":"10847_CR67","doi-asserted-by":"publisher","first-page":"2196","DOI":"10.1038\/s41467-025-57481-7","volume":"16","author":"A Greer-Short","year":"2025","unstructured":"Greer-Short A, Greenwood A, Leon EC, Qureshi TN, von Kraut K, Wong J, et al. AAV9-mediated MYBPC3 gene therapy with optimized expression cassette enhances cardiac function and survival in MYBPC3 cardiomyopathy models. Nat Commun. 2025;16(1):2196. https:\/\/doi.org\/10.1038\/s41467-025-57481-7.","journal-title":"Nat Commun"},{"key":"10847_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41551-025-01480-y","author":"S Xu","year":"2025","unstructured":"Xu S, Liang D, Wang Q, Cheng Y, Xie D, Gui Y, et al. In vivo genome editing of human haematopoietic stem cells for treatment of blood disorders using mRNA delivery. Nat Biomedical Eng. 2025. https:\/\/doi.org\/10.1038\/s41551-025-01480-y.","journal-title":"Nat Biomedical Eng"},{"issue":"8","key":"10847_CR69","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1007\/s12015-023-10585-3","volume":"19","author":"M Lotfi","year":"2023","unstructured":"Lotfi M, Morshedi Rad D, Mashhadi SS, Ashouri A, Mojarrad M, Mozaffari-Jovin S, et al. Recent Advances in CRISPR\/Cas9 Delivery Approaches for Therapeutic Gene Editing of Stem Cells. Stem Cell Rev Rep. 2023;19(8):2576\u201396. https:\/\/doi.org\/10.1007\/s12015-023-10585-3.","journal-title":"Stem Cell Rev Rep"},{"key":"10847_CR70","doi-asserted-by":"publisher","first-page":"673286","DOI":"10.3389\/fgene.2021.673286","volume":"12","author":"L Duan","year":"2021","unstructured":"Duan L, Ouyang K, Xu X, Xu L, Wen C, Zhou X, et al. Nanoparticle Delivery of CRISPR\/Cas9 for Genome Editing. Front Genet. 2021;12:673286. https:\/\/doi.org\/10.3389\/fgene.2021.673286.","journal-title":"Front Genet"},{"issue":"2","key":"10847_CR71","doi-asserted-by":"publisher","first-page":"e70091","DOI":"10.1002\/mco2.70091","volume":"6","author":"B Qie","year":"2025","unstructured":"Qie B, Tuo J, Chen F, Ding H, Lyu L. Gene therapy for genetic diseases: challenges and future directions. MedComm. 2025;6(2):e70091. https:\/\/doi.org\/10.1002\/mco2.70091.","journal-title":"MedComm"},{"issue":"5","key":"10847_CR72","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1161\/circulationaha.122.063759","volume":"148","author":"X Li","year":"2023","unstructured":"Li X, La Salvia S, Liang Y, Adamiak M, Kohlbrenner E, Jeong D, et al. Extracellular Vesicle-Encapsulated Adeno-Associated Viruses for Therapeutic Gene Delivery to the Heart. Circulation. 2023;148(5):405\u201325. https:\/\/doi.org\/10.1161\/circulationaha.122.063759.","journal-title":"Circulation"},{"issue":"2","key":"10847_CR73","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/hgtb.2012.243","volume":"24","author":"V Louis Jeune","year":"2013","unstructured":"Louis Jeune V, Joergensen JA, Hajjar RJ, Weber T. Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum Gene Ther Methods. 2013;24(2):59\u201367. https:\/\/doi.org\/10.1089\/hgtb.2012.243.","journal-title":"Hum Gene Ther Methods"},{"issue":"11","key":"10847_CR74","doi-asserted-by":"publisher","first-page":"e2307800120","DOI":"10.1073\/pnas.2307800120","volume":"121","author":"S Chatterjee","year":"2024","unstructured":"Chatterjee S, Kon E, Sharma P, Peer D. Endosomal escape: A bottleneck for LNP-mediated therapeutics. Proc Natl Acad Sci U S A. 2024;121(11):e2307800120. https:\/\/doi.org\/10.1073\/pnas.2307800120.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10847_CR75","doi-asserted-by":"publisher","unstructured":"Generalov E, Shevelev A, Romanov D, Tarasova O, Pozdniakova N. RNA therapeutics in viral infections and cancer: Mechanisms, challenges, and prospects: a review. Pharmaceutics. 2026;18(4). https:\/\/doi.org\/10.3390\/pharmaceutics18040431.","DOI":"10.3390\/pharmaceutics18040431"},{"key":"10847_CR76","doi-asserted-by":"publisher","first-page":"963689724124895","DOI":"10.1177\/09636897241248956","volume":"33","author":"AYL Wang","year":"2024","unstructured":"Wang AYL, Chang YC, Chen KH, Loh CYY. Potential Application of Modified mRNA in Cardiac Regeneration. Cell Transpl. 2024;33:9636897241248956. https:\/\/doi.org\/10.1177\/09636897241248956.","journal-title":"Cell Transpl"},{"key":"10847_CR77","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1017\/erm.2025.10","volume":"27","author":"B Cetin","year":"2025","unstructured":"Cetin B, Erendor F, Eksi YE, Sanlioglu AD, Sanlioglu S. Advancing CRISPR genome editing into gene therapy clinical trials: progress and future prospects. Expert Rev Mol Med. 2025;27:e16. https:\/\/doi.org\/10.1017\/erm.2025.10.","journal-title":"Expert Rev Mol Med"},{"issue":"8","key":"10847_CR78","doi-asserted-by":"publisher","first-page":"e71159","DOI":"10.1111\/jcmm.71159","volume":"30","author":"M Aliciaslan","year":"2026","unstructured":"Aliciaslan M, Erbasan E, Erendor F, Sanlioglu S. Advances in CRISPR Base Editing: From Molecular Evolution to Therapeutic Applications in Genomic Medicine. J Cell Mol Med. 2026;30(8):e71159. https:\/\/doi.org\/10.1111\/jcmm.71159.","journal-title":"J Cell Mol Med"},{"issue":"10","key":"10847_CR79","doi-asserted-by":"publisher","first-page":"e70040","DOI":"10.1002\/jgm.70040","volume":"27","author":"M Aliciaslan","year":"2025","unstructured":"Aliciaslan M, Erbasan E, Erendor F, Sanlioglu S. Prime Editing: The Next Frontier in Precision Gene Therapy. J Gene Med. 2025;27(10):e70040. https:\/\/doi.org\/10.1002\/jgm.70040.","journal-title":"J Gene Med"},{"issue":"1","key":"10847_CR80","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1146\/annurev-genet-011725-094039","volume":"59","author":"T Tadokoro","year":"2025","unstructured":"Tadokoro T, Olson EN, Liu N. Gene Editing Applications as Future Cardiovascular Therapies. Annu Rev Genet. 2025;59(1):119\u201345. https:\/\/doi.org\/10.1146\/annurev-genet-011725-094039.","journal-title":"Annu Rev Genet"},{"issue":"12","key":"10847_CR81","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1161\/CIRCRESAHA.122.320496","volume":"130","author":"N Liu","year":"2022","unstructured":"Liu N, Olson EN. CRISPR Modeling and Correction of Cardiovascular Disease. Circul Res. 2022;130(12):1827\u201350. https:\/\/doi.org\/10.1161\/CIRCRESAHA.122.320496.","journal-title":"Circul Res"},{"issue":"19","key":"10847_CR82","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1161\/CIRCULATIONAHA.123.065117","volume":"148","author":"S Lebek","year":"2023","unstructured":"Lebek S, Caravia XM, Chemello F, Tan W, McAnally JR, Chen K, et al. Elimination of CaMKII\u03b4 Autophosphorylation by CRISPR-Cas9 Base Editing Improves Survival and Cardiac Function in Heart Failure in Mice. Circulation. 2023;148(19):1490\u2013504. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.065117.","journal-title":"Circulation"},{"key":"10847_CR83","doi-asserted-by":"publisher","unstructured":"Lebek S, Caravia XM, Straub LG, Alzhanov D, Tan W, Li H, et al. CRISPR-Cas9 base editing of pathogenic CaMKII\u03b4 improves cardiac function in a humanized mouse model. J Clin Investig. 2023;134(1). https:\/\/doi.org\/10.1172\/JCI175164.","DOI":"10.1172\/JCI175164"},{"issue":"1","key":"10847_CR84","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.jacbts.2018.11.004","volume":"4","author":"DM German","year":"2019","unstructured":"German DM, Mitalipov S, Mishra A, Kaul S. Therapeutic Genome Editing in Cardiovascular Diseases. JACC Basic Transl Sci. 2019;4(1):122\u201331. https:\/\/doi.org\/10.1016\/j.jacbts.2018.11.004.","journal-title":"JACC Basic Transl Sci"},{"key":"10847_CR85","doi-asserted-by":"publisher","unstructured":"Musunuru K. Moving toward genome-editing therapies for cardiovascular diseases. J Clin Invest. 2022;132(1). https:\/\/doi.org\/10.1172\/jci148555.","DOI":"10.1172\/jci148555"},{"issue":"7448","key":"10847_CR86","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature12054","volume":"497","author":"AI Mahmoud","year":"2013","unstructured":"Mahmoud AI, Kocabas F, Muralidhar SA, Kimura W, Koura AS, Thet S, et al. Meis1 regulates postnatal cardiomyocyte cell cycle arrest. Nature. 2013;497(7448):249\u201353. https:\/\/doi.org\/10.1038\/nature12054.","journal-title":"Nature"},{"issue":"2","key":"10847_CR87","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cell.2013.06.044","volume":"154","author":"LA Gilbert","year":"2013","unstructured":"Gilbert LA, Larson MH, Morsut L, Liu Z, Brar GA, Torres SE, et al. CRISPR-mediated modular RNA-guided regulation of transcription in eukaryotes. Cell. 2013;154(2):442\u201351. https:\/\/doi.org\/10.1016\/j.cell.2013.06.044.","journal-title":"Cell"},{"issue":"3","key":"10847_CR88","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s11886-017-0830-5","volume":"19","author":"AC Chadwick","year":"2017","unstructured":"Chadwick AC, Musunuru K. Genome Editing for the Study of Cardiovascular Diseases. Curr Cardiol Rep. 2017;19(3):22. https:\/\/doi.org\/10.1007\/s11886-017-0830-5.","journal-title":"Curr Cardiol Rep"},{"key":"10847_CR89","doi-asserted-by":"publisher","unstructured":"Ball J, Bradley A, Le A, Tisdale JF, Uchida N. Hematopoietic stem cell therapy with gene modification to treat sickle cell disease. Stem Cells Transl Med. 2025;14(9). https:\/\/doi.org\/10.1093\/stcltm\/szaf042.","DOI":"10.1093\/stcltm\/szaf042"},{"issue":"6","key":"10847_CR90","doi-asserted-by":"publisher","first-page":"101068","DOI":"10.1016\/j.ajps.2025.101068","volume":"20","author":"P Yang","year":"2025","unstructured":"Yang P, Khoshandam M, Bhia I, Raji S, Soltaninejad H, Hosseinkhani S, et al. Integrating CRISPR\/Cas technology with clinical trials: Principles, progress and challenges. Asian J Pharm Sci. 2025;20(6):101068. https:\/\/doi.org\/10.1016\/j.ajps.2025.101068.","journal-title":"Asian J Pharm Sci"},{"issue":"2","key":"10847_CR91","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/s41591-018-0204-6","volume":"25","author":"DL Wagner","year":"2019","unstructured":"Wagner DL, Amini L, Wendering DJ, Burkhardt LM, Aky\u00fcz L, Reinke P, et al. High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population. Nat Med. 2019;25(2):242\u20138. https:\/\/doi.org\/10.1038\/s41591-018-0204-6.","journal-title":"Nat Med"},{"issue":"2","key":"10847_CR92","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","volume":"25","author":"CT Charlesworth","year":"2019","unstructured":"Charlesworth CT, Deshpande PS, Dever DP, Camarena J, Lemgart VT, Cromer MK, et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med. 2019;25(2):249\u201354. https:\/\/doi.org\/10.1038\/s41591-018-0326-x.","journal-title":"Nat Med"},{"issue":"5","key":"10847_CR93","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1016\/j.jtcvs.2015.07.035","volume":"150","author":"AC Gaffey","year":"2015","unstructured":"Gaffey AC, Chen MH, Venkataraman CM, Trubelja A, Rodell CB, Dinh PV, et al. Injectable shear-thinning hydrogels used to deliver endothelial progenitor cells, enhance cell engraftment, and improve ischemic myocardium. J Thorac Cardiovasc Surg. 2015;150(5):1268\u201376. https:\/\/doi.org\/10.1016\/j.jtcvs.2015.07.035.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"8","key":"10847_CR94","doi-asserted-by":"publisher","first-page":"8050","DOI":"10.1021\/nn5020787","volume":"8","author":"A Paul","year":"2014","unstructured":"Paul A, Hasan A, Kindi HA, Gaharwar AK, Rao VTS, Nikkhah M, et al. Injectable Graphene Oxide\/Hydrogel-Based Angiogenic Gene Delivery System for Vasculogenesis and Cardiac Repair. ACS Nano. 2014;8(8):8050\u201362. https:\/\/doi.org\/10.1021\/nn5020787.","journal-title":"ACS Nano"},{"issue":"1","key":"10847_CR95","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/gels7010007","volume":"7","author":"C Hoeeg","year":"2021","unstructured":"Hoeeg C, Dolatshahi-Pirouz A, Follin B. Injectable Hydrogels for Improving Cardiac Cell Therapy\u2014In Vivo Evidence and Translational Challenges. Gels. 2021;7(1):7.","journal-title":"Gels"},{"key":"10847_CR96","doi-asserted-by":"publisher","first-page":"133","DOI":"10.54097\/zg390z62","volume":"147","author":"Y Wang","year":"2025","unstructured":"Wang Y. Multifunctional Nanocomposites for Efficient Gene Delivery. Highlights in Science. Eng Technol. 2025;147:133\u201340. https:\/\/doi.org\/10.54097\/zg390z62.","journal-title":"Eng Technol"},{"key":"10847_CR97","doi-asserted-by":"publisher","DOI":"10.1002\/apj.70229","author":"M Shadi","year":"2026","unstructured":"Shadi M, Vafaei-Nezhad S, Ahangar A. Nanoclay-Engineered Scaffolds for the Controlled Delivery of Biomolecules in Regenerative Medicine. Asia-Pac J Chem Eng. 2026. https:\/\/doi.org\/10.1002\/apj.70229.","journal-title":"Asia-Pac J Chem Eng"},{"issue":"27","key":"10847_CR98","doi-asserted-by":"publisher","first-page":"2316675","DOI":"10.1002\/adfm.202316675","volume":"34","author":"Z Wang","year":"2024","unstructured":"Wang Z, Lao A, Huang X, Zhou Y, Shen SGF, Lin D. Apt-19s-Functionalized 3D-Printed Mesoporous Bioactive Glass Scaffold Promotes BMSC Recruitment in Bone Regeneration via SDF-1\u03b1\/CXCR4 Axis and MAPK Signaling. Adv Funct Mater. 2024;34(27):2316675. https:\/\/doi.org\/10.1002\/adfm.202316675.","journal-title":"Adv Funct Mater"},{"issue":"10","key":"10847_CR99","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1177\/0363546519856355","volume":"47","author":"X Wang","year":"2019","unstructured":"Wang X, Song X, Li T, Chen J, Cheng G, Yang L, et al. Aptamer-Functionalized Bioscaffold Enhances Cartilage Repair by Improving Stem Cell Recruitment in Osteochondral Defects of Rabbit Knees. Am J Sports Med. 2019;47(10):2316\u201326. https:\/\/doi.org\/10.1177\/0363546519856355.","journal-title":"Am J Sports Med"},{"key":"10847_CR100","doi-asserted-by":"publisher","unstructured":"Yang QD, Zhou JL, Yang M, Wei JY, Gui YT, Yang F, et al. A Di-aptamer-functionalized scaffold promotes bone regeneration by facilitating the selective retention of MSCs and EPCs and then promoting crosstalk between osteogenesis and angiogenesis. Biomaterials. 2025;319. https:\/\/doi.org\/10.1016\/j.biomaterials.2025.123197.","DOI":"10.1016\/j.biomaterials.2025.123197"},{"issue":"4","key":"10847_CR101","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1080\/07388551.2019.1572587","volume":"39","author":"D Kuraitis","year":"2019","unstructured":"Kuraitis D, Hosoyama K, Blackburn NJR, Deng C, Zhong Z, Suuronen EJ. Functionalization of soft materials for cardiac repair and regeneration. Crit Rev Biotechnol. 2019;39(4):451\u201368. https:\/\/doi.org\/10.1080\/07388551.2019.1572587.","journal-title":"Crit Rev Biotechnol"},{"issue":"2","key":"10847_CR102","doi-asserted-by":"publisher","first-page":"e10158","DOI":"10.1002\/btm2.10158","volume":"5","author":"A Mandal","year":"2020","unstructured":"Mandal A, Clegg JR, Anselmo AC, Mitragotri S. Hydrogels in the clinic. Bioeng Transl Med. 2020;5(2):e10158. https:\/\/doi.org\/10.1002\/btm2.10158.","journal-title":"Bioeng Transl Med"},{"key":"10847_CR103","doi-asserted-by":"publisher","DOI":"10.3390\/polym16081159","author":"G Satchanska","year":"2024","unstructured":"Satchanska G, Davidova S, Petrov PD. Natural and Synthetic Polymers for Biomedical and Environmental Applications. Polymers. 2024. https:\/\/doi.org\/10.3390\/polym16081159.","journal-title":"Polymers"},{"key":"10847_CR104","doi-asserted-by":"publisher","DOI":"10.3390\/polym18050581","author":"E Hurtado-Fern\u00e1ndez","year":"2026","unstructured":"Hurtado-Fern\u00e1ndez E, Trujillo-Cayado LA, \u00c1lvarez-Mateos P, Santos J. Extraction, Characterization and Applications of Biopolymers from Sustainable Sources. Polymers. 2026. https:\/\/doi.org\/10.3390\/polym18050581.","journal-title":"Polymers"},{"key":"10847_CR105","doi-asserted-by":"publisher","DOI":"10.3390\/polym18070842","author":"Y Basem","year":"2026","unstructured":"Basem Y, Ata A, Sabry F, Tamer M, Raaft E, Abdelmonem R. Sustainable Green Polymer Production for Pharmaceutical Manufacturing: A Review of Environmental and Economic Impacts. Polymers. 2026. https:\/\/doi.org\/10.3390\/polym18070842.","journal-title":"Polymers"},{"key":"10847_CR106","unstructured":"Biocardia I. Late Breaking Echocardiography Clinical Results from CardiAMP HF Trial Presented at Technology and Heart Failure Therapeutics (THT). (2026). https:\/\/www.biocardia.com\/investors\/press-releases\/id\/1037?pressReleaseId=253. Accessed 12 Mar 2026."},{"key":"10847_CR107","unstructured":"Biocardia I. BioCardia Announces Positive DSMB Review of CardiALLO Allogeneic Cell Therapy for Heart Failure Phase 1\/2 Clinical Trial. (2025). https:\/\/www.globenewswire.com\/news-release\/2025\/04\/15\/3061732\/0\/en\/BioCardia-Announces-Positive-DSMB-Review-of-CardiALLO-Allogeneic-Cell-Therapy-for-Heart-Failure-Phase-1-2-Clinical-Trial.html. 12 Accessed Mar 2026."},{"issue":"3","key":"10847_CR108","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.ahj.2009.12.021","volume":"159","author":"M Taljaard","year":"2010","unstructured":"Taljaard M, Ward MR, Kutryk MJ, Courtman DW, Camack NJ, Goodman SG, et al. Rationale and design of Enhanced Angiogenic Cell Therapy in Acute Myocardial Infarction (ENACT-AMI): the first randomized placebo-controlled trial of enhanced progenitor cell therapy for acute myocardial infarction. Am Heart J. 2010;159(3):354\u201360. https:\/\/doi.org\/10.1016\/j.ahj.2009.12.021.","journal-title":"Am Heart J"},{"issue":"5","key":"10847_CR109","doi-asserted-by":"publisher","first-page":"e014054","DOI":"10.1161\/circinterventions.124.014054","volume":"17","author":"K Nakamura","year":"2024","unstructured":"Nakamura K, Henry TD, Traverse JH, Latter DA, Mokadam NA, Answini GA, et al. Angiogenic Gene Therapy for Refractory Angina: Results of the EXACT Phase 2 Trial. Circ Cardiovasc Interv. 2024;17(5):e014054. https:\/\/doi.org\/10.1161\/circinterventions.124.014054.","journal-title":"Circ Cardiovasc Interv"},{"issue":"10","key":"10847_CR110","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1056\/NEJMoa2412392","volume":"392","author":"B Greenberg","year":"2025","unstructured":"Greenberg B, Taylor M, Adler E, Colan S, Ricks D, Yarabe P, et al. Phase 1 Study of AAV9.LAMP2B Gene Therapy in Danon Disease. N Engl J Med. 2025;392(10):972\u201383. https:\/\/doi.org\/10.1056\/NEJMoa2412392.","journal-title":"N Engl J Med"},{"issue":"4","key":"10847_CR111","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1002\/ehf2.14393","volume":"10","author":"A Reid","year":"2023","unstructured":"Reid A, Hussain M, Veerapen J, Ramaseshan R, Hall R, Bowles R, et al. DCM Support: cell therapy and circulatory support for dilated cardiomyopathy patients with severe ventricular impairment. ESC Heart Fail. 2023;10(4):2664\u201371. https:\/\/doi.org\/10.1002\/ehf2.14393.","journal-title":"ESC Heart Fail"},{"key":"10847_CR112","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ahj.2018.03.016","volume":"201","author":"AN Raval","year":"2018","unstructured":"Raval AN, Cook TD, Duckers HJ, Johnston PV, Traverse JH, Abraham WT, et al. The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post-myocardial infarction heart failure: Trial rationale and study design. Am Heart J. 2018;201:141\u20138. https:\/\/doi.org\/10.1016\/j.ahj.2018.03.016.","journal-title":"Am Heart J"},{"key":"10847_CR113","doi-asserted-by":"publisher","unstructured":"Pepine CJ, Raval AN. The CardiAMP Cell Therapy for Heart Failure trial. Tex Heart Inst J. 2023;50(5). https:\/\/doi.org\/10.14503\/thij-23-8242.","DOI":"10.14503\/thij-23-8242"},{"key":"10847_CR114","unstructured":"BioSpace. BioCardia Reports First Quarter 2026 Business Highlights and Financial Results. https:\/\/www.biospace.com\/press-releases\/biocardia-reports-first-quarter-2026-business-highlights-and-financial-results (2026). Accessed May 21 2026."},{"issue":"11","key":"10847_CR115","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1161\/circresaha.117.311827","volume":"121","author":"V Florea","year":"2017","unstructured":"Florea V, Rieger AC, DiFede DL, El-Khorazaty J, Natsumeda M, Banerjee MN, et al. Dose Comparison Study of Allogeneic Mesenchymal Stem Cells in Patients With Ischemic Cardiomyopathy (The TRIDENT Study). Circ Res. 2017;121(11):1279\u201390. https:\/\/doi.org\/10.1161\/circresaha.117.311827.","journal-title":"Circ Res"},{"issue":"12","key":"10847_CR116","doi-asserted-by":"publisher","first-page":"3288","DOI":"10.1002\/ejhf.3522","volume":"27","author":"EC Perin","year":"2025","unstructured":"Perin EC, Borow KM, Henry TD, Jenkins M, Rutman O, Hayes J, et al. Mesenchymal precursor cells reduce mortality and major morbidity in ischaemic heart failure with inflammation: DREAM-HF. Eur J Heart Fail. 2025;27(12):3288\u201396. https:\/\/doi.org\/10.1002\/ejhf.3522.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10847_CR117","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1161\/CIRCRESAHA.113.300219","volume":"113","author":"SK Sanganalmath","year":"2013","unstructured":"Sanganalmath SK, Bolli R. Cell Therapy for Heart Failure. Circul Res. 2013;113(6):810\u201334. https:\/\/doi.org\/10.1161\/CIRCRESAHA.113.300219.","journal-title":"Circul Res"},{"issue":"10","key":"10847_CR118","doi-asserted-by":"publisher","first-page":"S176","DOI":"10.1016\/j.cjca.2022.08.135","volume":"38","author":"S Pasricha","year":"2022","unstructured":"Pasricha S, Kutryk M, Akhavein F, Ly H, Leong-Poi H, Dick A, et al. Endothelial progenitor cells engineered to over-express endothelial no-synthase and their effect on arrhythmic substrate as assessed by gray zone analysis - a sub-study of the ENACT-AMI trial. Can J Cardiol. 2022;38(10):S176. https:\/\/doi.org\/10.1016\/j.cjca.2022.08.135.","journal-title":"Can J Cardiol"},{"key":"10847_CR119","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ahj.2021.06.013","volume":"241","author":"TJ Povsic","year":"2021","unstructured":"Povsic TJ, Henry TD, Ohman EM, Pepine CJ, Crystal RG, Rosengart TK, et al. Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): Rationale, design, and clinical considerations. Am Heart J. 2021;241:38\u201349. https:\/\/doi.org\/10.1016\/j.ahj.2021.06.013.","journal-title":"Am Heart J"},{"key":"10847_CR120","unstructured":"FDA: Considerations for the use of the Plausible Mechanism. Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause. (2026). https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-use-plausible-mechanism-framework-develop-individualized-therapies-target-specific. 21 Accessed May 2026."},{"key":"10847_CR121","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/10_2017_14","volume":"165","author":"E Abraham","year":"2018","unstructured":"Abraham E, Ahmadian BB, Holderness K, Levinson Y, McAfee E. Platforms for Manufacturing Allogeneic, Autologous and iPSC Cell Therapy Products: An Industry Perspective. Adv Biochem Eng Biotechnol. 2018;165:323\u201350. https:\/\/doi.org\/10.1007\/10_2017_14.","journal-title":"Adv Biochem Eng Biotechnol"},{"issue":"11","key":"10847_CR122","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1007\/s10529-019-02732-z","volume":"41","author":"P Moutsatsou","year":"2019","unstructured":"Moutsatsou P, Ochs J, Schmitt RH, Hewitt CJ, Hanga MP. Automation in cell and gene therapy manufacturing: from past to future. Biotechnol Lett. 2019;41(11):1245\u201353. https:\/\/doi.org\/10.1007\/s10529-019-02732-z.","journal-title":"Biotechnol Lett"},{"key":"10847_CR123","doi-asserted-by":"publisher","first-page":"1005457","DOI":"10.3389\/fimmu.2022.1005457","volume":"13","author":"N Martinez-Cibrian","year":"2022","unstructured":"Martinez-Cibrian N, Espa\u00f1ol-Rego M, Pascal M, Delgado J, Ortiz-Maldonado V. Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing. Front Immunol. 2022;13:1005457. https:\/\/doi.org\/10.3389\/fimmu.2022.1005457.","journal-title":"Front Immunol"},{"issue":"11","key":"10847_CR124","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1182\/bloodadvances.2024013656","volume":"9","author":"FL Locke","year":"2025","unstructured":"Locke FL, Siddiqi T, Jacobson CA, Nikiforow S, Ahmed S, Miklos DB, et al. Impact of vein-to-vein time in patients with R\/R LBCL treated with axicabtagene ciloleucel. Blood Adv. 2025;9(11):2663\u201376. https:\/\/doi.org\/10.1182\/bloodadvances.2024013656.","journal-title":"Blood Adv"},{"issue":"7412","key":"10847_CR125","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/nature11396","volume":"488","author":"A Kong","year":"2012","unstructured":"Kong A, Frigge ML, Masson G, Besenbacher S, Sulem P, Magnusson G, et al. Rate of de novo mutations and the importance of father\u2019s age to disease risk. Nature. 2012;488(7412):471\u20135. https:\/\/doi.org\/10.1038\/nature11396.","journal-title":"Nature"},{"issue":"6576","key":"10847_CR126","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik JG, Tomb\u00e1cz I, Yadegari A, M\u00e9ndez Fern\u00e1ndez PO, Shewale SV, Li L, et al. CAR T cells produced in vivo to treat cardiac injury. Science. 2022;375(6576):91\u20136. https:\/\/doi.org\/10.1126\/science.abm0594.","journal-title":"Science"},{"key":"10847_CR127","doi-asserted-by":"publisher","first-page":"659890","DOI":"10.1155\/2015\/659890","volume":"2015","author":"K Kang","year":"2015","unstructured":"Kang K, Ma R, Cai W, Huang W, Paul C, Liang J, et al. Exosomes Secreted from CXCR4 Overexpressing Mesenchymal Stem Cells Promote Cardioprotection via Akt Signaling Pathway following Myocardial Infarction. Stem Cells Int. 2015;2015:659890. https:\/\/doi.org\/10.1155\/2015\/659890.","journal-title":"Stem Cells Int"},{"issue":"10","key":"10847_CR128","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.stemcr.2024.08.002","volume":"19","author":"K Nakano","year":"2024","unstructured":"Nakano K, Sadahiro T, Fujita R, Isomi M, Abe Y, Yamada Y, et al. Development of adeno-associated viral vectors targeting cardiac fibroblasts for efficient in vivo cardiac reprogramming. Stem Cell Rep. 2024;19(10):1389\u201398. https:\/\/doi.org\/10.1016\/j.stemcr.2024.08.002.","journal-title":"Stem Cell Rep"},{"key":"10847_CR129","doi-asserted-by":"publisher","unstructured":"Vall\u00e9e A. Multi-scale digital twins for personalized medicine. Front Digit Health. 2026;8\u20132026. https:\/\/doi.org\/10.3389\/fdgth.2026.1753906.","DOI":"10.3389\/fdgth.2026.1753906"},{"issue":"1","key":"10847_CR130","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s44161-025-00757-4","volume":"5","author":"K Rjoob","year":"2026","unstructured":"Rjoob K, McGurk KA, Zheng SL, Curran L, Ibrahim M, Zeng L, et al. A multimodal vision knowledge graph of cardiovascular disease. Nat Cardiovasc Res. 2026;5(1):18\u201333. https:\/\/doi.org\/10.1038\/s44161-025-00757-4.","journal-title":"Nat Cardiovasc Res"}],"container-title":["Journal of Cardiovascular Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-026-10847-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12265-026-10847-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12265-026-10847-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:36:51Z","timestamp":1790347011000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12265-026-10847-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":130,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["10847"],"URL":"https:\/\/doi.org\/10.1007\/s12265-026-10847-8","relation":{},"ISSN":["1937-5387","1937-5395"],"issn-type":[{"value":"1937-5387","type":"print"},{"value":"1937-5395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors have read and approved the final manuscript and provide their full consent for publication.","order":1,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study did not involve human participants or animals.","order":2,"name":"Ethics","label":"<b>Research Involving Human Participants and\/or Animals<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":3,"name":"Ethics","label":"<b>Competing interests<\/b>","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"121"}}